



We claim:

1. A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H<sub>3</sub> receptor antagonist / m<sub>2</sub> muscarinic antagonist.

2. The method of claim 1 wherein the dual H<sub>3</sub>/m<sub>2</sub> antagonist is selected from the group consisting of





and

5 3. A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a combination of an histamine H<sub>3</sub> receptor antagonist and a m<sub>2</sub> muscarinic antagonist.

10 4. The method of claim 3 wherein the histamine H<sub>3</sub> receptor antagonist is selected from the group consisting of thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, ciproxifam, SKF-91486, GR-175737, GT-2016, GT-2331, UCL-1199, clozapine and those of formula VIII and IX.

15 5. The method of claim 4 wherein the histamine H<sub>3</sub> antagonist is selected from the group consisting of clobenpropit, impromidine, GT-2331, GR-175737, UCL-1199 and those of formula VIII and IX.


20 6. The method of claim 3 wherein the m<sub>2</sub> muscarinic antagonist is selected from the compounds of the formula IA-1.

25 7. The method of claim 6 wherein the histamine H<sub>3</sub> receptor antagonist is selected from the group consisting of thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, ciproxifam,

SKF-91486, GR-175737, GT-2016, GT-2331, UCL-1199, clozapine and those of formula VIII and IX.

8. The method of claim 7 wherein the histamine H<sub>3</sub> antagonist is selected from the group consisting of clobenpropit, impromidine, GT-2331, GR-175737, UCL-1199 and those of formula VIII and IX.


9. The method of claim 3 wherein the histamine H<sub>3</sub> antagonist is selected from the group consisting of clobenpropit, impromidine, GT-2331, GR-175737, UCL-1199 and those of formula VIII and IX, and the m<sub>2</sub> antagonist is



10. A pharmaceutical composition comprising an effective amount of a combination of a histamine H<sub>3</sub> antagonist and a m<sub>2</sub> muscarinic antagonist, and a pharmaceutically acceptable carrier.

11. The composition of claim 10 wherein the histamine H<sub>3</sub> receptor antagonist is selected from the group consisting of thioperamide, impromidine, burimamide, clobenpropit, impentamine, mifetidine, S-sopromidine, R-sopromidine, ciproxifam, SKF-91486, GR-175737, GT-2016, GT-2331, UCL-1199, clozapine and those of formula VIII and IX; and wherein the m<sub>2</sub> muscarinic antagonist is selected from the compounds of formula IA-1.

12. The composition of claim 11 wherein the histamine H<sub>3</sub> antagonist is selected from the group consisting of clobenpropit, impromidine, GT-2331, GR-175737, UCL-1199 and those of formula VIII and IX and the m<sub>2</sub> antagonist is



13. A kit comprising in a single package, one container comprising a histamine H<sub>3</sub> antagonist in a pharmaceutically acceptable carrier, and a separate container comprising a m<sub>2</sub> muscarinic antagonist in a pharmaceutically acceptable carrier, with

the  $H_3$  and  $m_2$  antagonists being present in amounts such that the combination is effective to treat cognition deficit disorders.

14. A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine  $H_3$  antagonist/ $m_2$  muscarinic antagonist or an effective amount of a combination of a histamine  $H_3$  receptor antagonist and a  $m_2$  muscarinic antagonist, in combination with an effective amount of an acetylcholinesterase inhibitor.

15. A pharmaceutical composition comprising an effective amount of a dual histamine  $H_3$  antagonist/  $m_2$  muscarinic antagonist or a combination of a histamine  $H_3$  antagonist and a  $m_2$  muscarinic antagonist, in further combination with an acetylcholinesterase inhibitor and a pharmaceutically acceptable carrier.

16. A kit comprising, in a single package, one container comprising a dual histamine  $H_3$  antagonist/  $m_2$  muscarinic antagonist in a pharmaceutically acceptable carrier, or separate containers comprising a histamine  $H_3$  antagonist in a pharmaceutically acceptable carrier and a  $m_2$  muscarinic antagonist in a pharmaceutically acceptable carrier, and another container comprising an acetylcholinesterase inhibitor in a pharmaceutically acceptable carrier.